Odyssey Therapeutics, Inc. quarterly report, Q1 FY2026

Business Context and Reporting Period

Company: Odyssey Therapeutics, Inc. (ODTX)
Filing Type: Form 10-Q (Unaudited)
Period Ended: March 31, 2026
Business Overview: Odyssey is a clinical-stage biopharmaceutical company focused on autoimmune and inflammatory diseases. Its most advanced programs are OD-001 (RIPK2 inhibitor, Phase 2a for ulcerative colitis) and OD-002 (SLC15A4 inhibitor, IND-enabling studies). The company has no approved products and has not generated revenue from product sales.

Key Financial Metrics

Metric (in thousands) Q1 2026 Q1 2025
Collaboration Revenue $0 $1,918
Net Loss $(38,262) $(38,435)
Operating Loss $(39,780) $(39,160)
Research & Development Expenses $32,321 $38,774
General & Administrative Expenses $7,350 $7,952
Cash, Cash Equivalents & Marketable Securities $175,749 $206,556
Accumulated Deficit $(606,401) $(457,927)
Net Cash Used in Operating Activities $(41,035) $(38,621)

Note: The filing does not provide a specific "profit margin" as the company is pre-revenue and operating at a loss.

Material Changes vs. Prior Period

  • Revenue: Collaboration revenue decreased by $1.9 million to $0. This was due to the fulfillment of obligations under the Johnson & Johnson (J&J) agreement and the expiration of the Pfizer Material Transfer Agreement (MTA) during the prior year.
  • Operating Expenses: Total operating expenses decreased by $1.3 million.
    • R&D Expenses: Decreased by $6.5 million, primarily driven by a $6.3 million reduction in facility-related costs (due to a $5.4 million impairment of a San Diego lease ROU asset in Q1 2025) and lower personnel costs. This was partially offset by a $3.0 million increase in external clinical study expenses for the OD-001 Phase 2a trial.
    • G&A Expenses: Decreased by $0.6 million, mainly due to lower payroll and facility costs.
    • Contingent Consideration: The change in fair value shifted from a $5.6 million gain in Q1 2025 to a $0.1 million expense in Q1 2026, driven by changes in valuation assumptions regarding milestone probabilities and timing.
  • Liquidity: Cash and marketable securities decreased by approximately $30.8 million quarter-over-quarter, primarily due to operating cash burn, partially offset by maturities of marketable securities.

Guidance, Outlook, and Risks

  • Subsequent Events (IPO): In May 2026, the company completed its Initial Public Offering (IPO), raising approximately $255.4 million in net proceeds. A concurrent private placement raised an additional $23.3 million, and an underwriter option exercise in June 2026 raised $10.0 million. Total net proceeds from these events were approximately $288.7 million.
  • Liquidity Outlook: Management believes that existing cash resources ($175.7 million as of March 31, 2026) combined with IPO proceeds will fund operations into the second half of 2028.
  • Key Risks:
    • Development Risk: No products are approved; success depends entirely on OD-001 and OD-002 completing clinical trials and receiving regulatory approval.
    • Capital Requirements: The company expects to incur substantial losses for the foreseeable future and will require additional capital to fund operations beyond the current runway.
    • Third-Party Reliance: Reliance on CROs and CMOs for clinical trials and manufacturing introduces risks of delays or quality issues.
    • Geopolitical Factors: Clinical trial sites in Ukraine and reliance on CROs in China expose the company to geopolitical risks.

Investor Verification Checklist

  • Runway Validation: Verify the specific burn rate assumptions used to project funding sufficiency into late 2028, given the high variability of clinical trial costs.
  • OD-001 Trial Status: Confirm the current enrollment status and data readout timeline for the Phase 2a ulcerative colitis trial, as this is the primary value driver.
  • Contingent Liabilities: Review the specific milestones triggering the $30 million contingent consideration payments to IFM Discovery and Rahko Limited shareholders.
  • Post-IPO Capital Structure: Confirm the final share count and dilution impact following the conversion of all preferred stock and warrants into common stock upon the IPO closing.
  • Lease Obligations: Assess the impact of the San Diego lease impairment and remaining lease commitments on future cash flows.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.